This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
Male or female subjects, ≥ 18 years
Advanced solid tumors with TP53 Y220C mutation
Previously treated with one or more lines of anticancer therapy and progressive disease
At least one measurable lesion according to RECIST version 1.1 criteria
Known CNS primary tumor and active or untreated CNS metastases
History of another primary malignancy that has been diagnosed or required therapy within the past 2 years
Toxicities of prior therapy have not been resolved to ≤ Grade 1 or to baseline
Significant cardiovascular disease, including congestive heart failure